Chelation therapy with oral solution of deferiprone in transfusional iron-overloaded children with hemoglobinopathies

Anemia

Volumn 2013, Issue , 2013, Pages

  Makis, Alexandros ^a,b   Chaliasos, Nikolaos ^a,b   Alfantaki, Sapfo ^a   Karagouni, Paraskevi ^a   Siamopoulou, Antigone ^a,b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84888862938     PISSN: 20901267     EISSN: 20901275     Source Type: Journal    
DOI: 10.1155/2013/121762     Document Type: Article

References (8)

1. Hershko C., Pathogenesis and management of iron toxicity in thalassemia. Annals of the New York Academy of Sciences 2010 1202 1 9 2-s2.0-77955915545 10.1111/j.1749-6632.2010.05544.x
2. Olivieri N. F., Buncic J. R., Chew E., Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. The New England Journal of Medicine 1986 314 14 869 873 2-s2.0-0022628511 (Pubitemid 16126113)
3. De Virgiliis S., Congia M., Frau F., Argiolu F., Diana G., Cucca F., Varsi A., Sanna G., Podda G., Fodde M., Pirastu G. F., Cao A., Deferoxamine-induced growth retardation in patients with thalassemia major. Journal of Pediatrics 1988 113 4 661 669 2-s2.0-0023708159
4. Pennell D. J., Berdoukas V., Karagiorga M., Ladis V., Piga A., Aessopos A., Gotsis E. D., Tanner M. A., Smith G. C., Westwood M. A., Wonke B., Galanello R., Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006 107 9 3738 3744 2-s2.0-33646387405 10.1182/blood-2005-07-2948
5. Tanner M. A., Galanello R., Dessi C., Smith G. C., Westwood M. A., Agus A., Roughton M., Assomull R., Nair S. V., Walker J. M., Pennell D. J., A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007 115 14 1876 1884 2-s2.0-34247103036 10.1161/CIRCULATIONAHA.106.648790 (Pubitemid 46598901)
6. Naithani R., Chandra J., Sharma S., Safety of oral iron chelator deferiprone in young thalassaemics. European Journal of Haematology 2005 74 3 217 220 2-s2.0-14044266868 10.1111/j.1600-0609.2004.00377.x (Pubitemid 40278491)
7. Won S. C., Han D. K., Seo J. J., Efficacy and safety of deferiprone (Ferriprox), an oral iron-chelating agent, in pediatric patients. Korean Journal of Hematology 2010 45 58 61
8. El Alfy M., Sari T. T., Lee C. L., Tricta F., El-Beshlawy A., The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. Journal of Pediatric Hematology/Oncology 2010 32 8 601 605 2-s2.0-78349283049 10.1097/MPH. 0b013e3181ec0f13